In a long-term safety analysis, the most frequent AEs associated with sarilumab were neutropenia, increased alanine aminotransferase, injection site erythema, upper respiratory infections, urinary tract infections, nasopharyngitis, and bronchitis [21, 23, 24]. This evidence concerns the gene GPT and respiratory tract infectious disorder.